CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
AstraZeneca
Acerta Pharma BV
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Novartis
Juno Therapeutics, a Subsidiary of Celgene
Cothera Bioscience, Inc
Zhejiang DTRM Biopharma
Oncternal Therapeutics, Inc
Celgene
AO GENERIUM
Nordic Nanovector
Celgene
Oncternal Therapeutics, Inc
Takeda
miRagen Therapeutics, Inc.
AbbVie
Takeda
miRagen Therapeutics, Inc.
Amgen Research (Munich) GmbH
LEO Pharma
Seagen Inc.
Seagen Inc.
Nordic Nanovector
Eisai Inc.
Amgen Research (Munich) GmbH
Amgen Research (Munich) GmbH
Amgen Research (Munich) GmbH
Amgen Research (Munich) GmbH
Novartis
Seagen Inc.
Seagen Inc.
Seagen Inc.
Seagen Inc.
Seagen Inc.
Ariad Pharmaceuticals
AVEO Pharmaceuticals, Inc.
Antisoma Research